DWA
CSBR icon

Dorsey Wright & Associates’s Champions Oncology CSBR Stock Holding History

Dorsey Wright & Associates’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,159
Closed -$20K – 284
2018
Q3 		$20K Buy
+1,159
New +$10.3K ﹤0.01% 159

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Dorsey Wright & Associates's CSBR Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Champions Oncology (CSBR) in Q4 2018, closing a stake of 1,159 shares — an estimated $20K sold.

Dorsey Wright & Associates first reported a position in CSBR in Q3 2018 and held it in 1 quarter. The position peaked at $20K in Q3 2018. 45 funds tracked by Wall St. Rank hold CSBR as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Champions Oncology position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,159 Champions Oncology shares in Q4 2018, an estimated $20K.
  • Dorsey Wright & Associates first reported a position in Champions Oncology in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Champions Oncology position peaked at $20K in Q3 2018.
  • 45 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.